$PRCT pretty undervalued at these levels.

Procept BioRobotics is positioned around Aquablation therapy, a robot-assisted, image-guided waterjet treatment for benign prostatic hyperplasia (BPH).
Unlike heat-based or implant therapies, Aquablation uses real-time imaging + robotic precision to selectively remove prostate tissue while aiming to reduce risk of sexual side effects and preserve continence.
Key drivers:
• Still low penetration in a large, under-treated BPH surgery market
• Growing adoption in hospital urology departments as systems gain procedural experience
• Included as an established surgical option in major urology treatment pathways (alongside TURP and newer minimally invasive options)
• Expansion depends on installed base of robotic systems and recurring procedure utilization
Fundamentals are great.
Looks like good spot to bid TA wise💰